基于三重協同機制，埃萬妥單抗聯合療法或可重塑中國EGFR突變晚期NSCLC一線治療格局

EGFR/MET雙特異性抗體埃萬妥單抗實現了EGFR突變晚期NSCLC廣泛覆蓋。

*以下內容僅供醫療衛生專業人士瀏覽。

審批編碼：CP-555414
批準分發日期：2025/11/28
有效期：2026/11/28

參考文獻：

[1]Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.

[2]Lu S, Byoung CC, Jong-Seok L, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Aisa. LBA10.

[3]Felip E, Cho BC, Gutiérrez V, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024;35(9):805-816.

[4]Cho BC, Lu S, Felip E, et al. Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study. 2025 ELCC. 4O.

[5]中國醫藥教育協會肺癌醫學教育專業委員會,北京醫學獎勵基金會肺癌醫學青年專家委員會腦轉移協作組,支修益,et al.中國驅動基因陽性非小細胞肺癌腦轉移臨床診療指南(2025版)[J].中國肺癌雜志,2025,28(1):1-21.

[6]Shirish MG, Byoung CC, Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study. 2024 WCLC. OA.02.03.

[7]Zhou CC, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.

[8]Caicun Zhou , et al. Amivantamab Plus Chemotherapy vs Chemotherapy as a First-line Treatment Among Asian Patients With EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): PAPILLON Subgroup Analysis. 2023 ESMO Asia. 513 MO.

[9]Passaro A, Wang J, Wang Y, et, al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.

[10]Shih J, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.

[11]Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis. Mol Cancer Ther. 2020;19(10):2044-2056.

[12]Zhou Q, Zhao H, Lu S, et al. Consensus on the lung cancer management after third-generation EGFR-TKI resistance. Lancet Reg Health West Pac. 2024;53:101260.

[13]Brazel D, Nagasaka M. The development of amivantamab for the treatment of non-small cell lung cancer. Respir Res. 2023 Oct 25;24(1):256.

*“醫學界”力求所發表內容專業、可靠，但不對內容的準確性做出承諾；請相關各方在采用或以此作為決策依據時另行核查。